Jazz Pharmaceuticals (JAZZ) vs Dr. Reddy's Laboratories (RDY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Jazz Pharmaceuticals (JAZZ) has outperformed Dr. Reddy's Laboratories (RDY) over the past year, gaining 68.4% versus a loss of 12.5%. Over five years, JAZZ leads with a +64.3% price change compared with -7.1% for RDY. Jazz Pharmaceuticals is the larger company by market cap ($14.44 billion vs $10.16 billion), about 1.4 times the size, while Dr. Reddy's Laboratories is growing revenue faster (+13.8% vs +4.9%).
On valuation, Jazz Pharmaceuticals trades at a lower forward P/E (8.6x vs 18.9x for Dr. Reddy's Laboratories). Dr. Reddy's Laboratories pays a dividend yielding 65.57%, while Jazz Pharmaceuticals does not currently pay one. Dr. Reddy's Laboratories converts more of its revenue into profit, with a net margin of 17.4% versus -8.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | JAZZ | RDY |
|---|---|---|
| Share price | $222.45 | $12.20 |
| Market cap | $14.44B | $10.16B |
| 1-day change | -3.78% | -0.57% |
| YTD return | +35.99% | -12.61% |
| 1-year return | +68.36% | -12.54% |
| 5-year return | +64.31% | -7.06% |
| P/E ratio (TTM) | 15.25 | 27.73 |
| Forward P/E | 8.58 | 18.94 |
| EPS (TTM) | $14.59 | $0.44 |
| Dividend yield | 0.00% | 65.57% |
| Annual dividend | $0.00 | $8.00 |
| Revenue (latest FY) | $4.27B | $3.81B |
| Revenue growth (YoY) | +4.88% | +13.76% |
| Net income (latest FY) | $-356.15M | $663.00M |
| Gross margin | — | 58.51% |
| Operating margin | -10.08% | 22.09% |
| Net margin | -8.35% | 17.40% |
| 52-week high | $266.38 | $15.67 |
| 52-week low | $128.80 | $11.36 |
| Distance from 52-week high | -16.49% | -22.14% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +32.39% | +8.36% |
| Average volume | 850.55K | 2.89M |
| Shares outstanding | 64.91M | 832.99M |
| Employees | 2,890 | 27,527 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JAZZ has outperformed RDY by 80.9 percentage points over the past year.
- Dr. Reddy's Laboratories trades at a higher earnings multiple (27.7x vs 15.2x trailing P/E).
- Dr. Reddy's Laboratories offers a meaningfully higher dividend yield (65.57% vs 0.00%).
- Dr. Reddy's Laboratories is more profitable, keeping 17.4 cents of every revenue dollar as net income versus -8.3 cents for Jazz Pharmaceuticals.
- Dr. Reddy's Laboratories grew revenue faster in its latest fiscal year (+13.76% vs +4.88%).
About Jazz Pharmaceuticals
JAZZ stock →Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,890 employees
About Dr. Reddy's Laboratories
RDY stock →Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally.
Health Care · Biotechnology: Pharmaceutical Preparations · 27,527 employees
JAZZ vs RDY FAQ
Which is bigger, Jazz Pharmaceuticals or Dr. Reddy's Laboratories?
Jazz Pharmaceuticals (JAZZ) is larger, with a market capitalization of $14.44B compared with $10.16B for Dr. Reddy's Laboratories (RDY).
Which stock has performed better over the past year, JAZZ or RDY?
JAZZ returned +68.36% over the past 12 months, compared with -12.54% for RDY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, JAZZ or RDY?
JAZZ has the lower trailing P/E at 15.2, versus 27.7 for RDY. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Jazz Pharmaceuticals or Dr. Reddy's Laboratories?
Dr. Reddy's Laboratories pays a dividend yielding 65.57%, while Jazz Pharmaceuticals does not currently pay a regular dividend.
Are Jazz Pharmaceuticals and Dr. Reddy's Laboratories in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.